Review Article
Prognostic and Clinical Significance of Aspartate Aminotransferase-to-Lymphocyte Ratio Index in Individuals with Liver Cancer: A Meta-Analysis
Table 2
Subgroup analysis of pooled HRs and 95% CIs between ALRI and OS and PFS in hepatocellular carcinoma.
| Variables | No. of studies | No. of patients | Effects model | HR (95% CI) | | Heterogeneity | 2 (%) | |
| OS | | | | | | | | Total | 11 | 3914 | Random | 1.53 (1.25-1.82) | <0.001 | 80.4 | <0.001 | Treatment | | | | | | | | Surgical resection | 8 | 3218 | Random | 1.49 (1.17-1.81) | <0.001 | 82.7 | <0.001 | TACE | 2 | 267 | Random | 2.20 (1.19-3.22) | <0.001 | 0 | 0.940 | Palliative treatments | 1 | 429 | _ | | 0.004 | _ | _ | Staging criteria | | | | | | | | AJCC/NA | 6 | 1960 | Random | 1.60 (1.38-1.81) | <0.001 | 0 | 0.823 | BCLC | 5 | 2060 | Random | 1.56 (1.20-1.91) | <0.001 | 43.3 | 0.133 | Milan criteria | 1 | 241 | _ | 1.02 (1.01-1.02) | <0.001 | _ | _ | Sample size | | | | | | | | <230 | 4 | 664 | Random | 1.82 (1.29-2.34) | <0.001 | 0 | 0.701 | ≥230 | 7 | 3250 | Random | 1.45 (1.14-1.76) | <0.001 | 85.2 | <0.001 | Cut-off value of ALRI | | | | | | | | <26 | 5 | 1534 | Random | 1.51 (1.21-1.80) | <0.001 | 31.4 | 0.212 | ≥26 | 6 | 2380 | Random | 1.54 (1.12-1.96) | <0.001 | 83.3 | <0.001 | Cut-off selection | | | | | | | | ROC analysis | 8 | 2501 | Random | 1.49 (1.31-1.68) | <0.001 | 0 | 0.441 | R software | 1 | 189 | _ | 2.18 (1.30-3.65) | 0.003 | _ | _ | Mean value | 1 | 241 | _ | 1.02 (1.01-1.02) | <0.001 | _ | _ | X-tile | 1 | 983 | _ | 1.76 (1.42-2.17) | <0.001 | | | NOS score | | | | | | | | <8 | 2 | 612 | Random | 1.24 (0.73-1.76) | <0.001 | 84 | 0.012 | ≥8 | 9 | 3302 | Random | 1.58 (1.37-1.78) | <0.001 | 16.3 | 0.298 | PFS | | | | | | | | Total | 7 | 2899 | Random | 1.36 (1.10-1.63) | <0.001 | 81.8 | <0.001 | Treatment | | | | | | | | Surgical resection | 6 | 2821 | Random | 1.35 (1.08-1.61) | <0.001 | 84 | <0.001 | TACE | 1 | 78 | _ | 2.21 (1.04-4.71) | 0.040 | _ | _ | Staging criteria | | | | | | | | NA | 2 | 787 | Random | 1.60 (1.31-1.89) | <0.001 | 0 | 0.521 | BCLC | 4 | 1871 | Random | 1.37 (1.18-1.55) | <0.001 | 0 | 0.651 | Milan criteria | 1 | 241 | _ | 1.01 (1.01-1.02) | <0.001 | _ | _ | Sample size | | | | | | | | <230 | 1 | 78 | _ | 2.21 (1.04-4.71) | 0.040 | _ | _ | ≥230 | 6 | 2821 | Random | 1.35 (1.08-1.61) | <0.001 | 84 | <0.001 | Cut-off value of ALRI | | | | | | | | <26 | 4 | 1328 | Random | 1.48 (1.21-1.74) | <0.001 | 18.7 | 0.297 | ≥26 | 3 | 1571 | Random | 1.24 (0.92-1.57) | <0.001 | 85.5 | 0.001 | Cut-off selection | | | | | | | | ROC analysis | 5 | 1675 | Random | 1.46 (1.26-1.66) | <0.001 | 0 | 0.448 | Mean value | 1 | 241 | _ | 1.01 (1.01-1.02) | <0.001 | _ | _ | X-tile | 1 | 983 | _ | 1.39 (1.17-1.65) | <0.001 | _ | _ | NOS score | | | | | | | | <8 | 2 | 612 | Random | 1.22 (0.73-1.70) | <0.001 | 82.9 | 0.016 | ≥8 | 5 | 1524 | Random | 1.42 (1.25-1.58) | <0.001 | 0 | 0.443 |
|
|